CDMO and CRO selection should be evaluated as a regulatory and quality decision first, and a procurement decision second, using inspection history and oversight model design as the evaluative frame.
White Paper
Your CDMO Is Part of Your Regulatory Strategy
Related Resources
All Resources
case-study
Syner-G Partners with Leading Supplier in Life Sciences to Build Out New cGMP Compliant Facilities
Read More
case-study
Mobilizing Pharmaceutical Technology Transfers to a Contract Development and Manufacturing Organization (CDMO)
Read More
post
CFD Applications in Design of Manufacturing Processes and Facilities
Read More
post
How Regulatory Strategy Drives Innovation in Biopharma
Read More
Let's move from science to success.
Let’s Talk